In this Editor’s Special of The HemOnc Pulse , Tycel Phillips, MD, joins an editor of Blood Cancers Today to break down the latest research in B-cell non-Hodgkin lymphoma presented at the 2025 ASCO Annual Meeting. The conversation spans follicular lymphoma, CLL, mantle cell lymphoma, and large B-cell lymphoma, covering key insights on BTK/BCL2 inhibitors, bispecifics, CAR T-cell therapy, and more.
Hematologist-oncologist Dr. Alexey Danilov shares expert insights on chronic lymphocytic leukemia, highlighting unmet needs in immune management, the challenges of Richter’s transformation, and promising data on BTK degraders for double-refractory patients.
Saad Usmani, MD, MBA leads an in-depth discussion with a panel of leading myeloma experts; Dr. Caitlin Costello, Dr. Binod Dhakal, Dr. Pete Voorhees, and Dr. Shambavi Richard on the evolving landscape of frontline multiple myeloma treatment. The conversation covers the rationale behind quadruplet therapy, the integration of minimal residual disease as a response-adaptive strategy, and shifting perspectives on transplant eligibility and timing. Drawing on recent clinical trial data and personal c...
In this Editor’s Special of The HemOnc Pulse , Blood Cancers Today Managing Editor, Nichole Tucker speaks with Amir Fathi, MD, of Massachusetts General Hospital, about key updates in AML from ASCO 2025. The discussion centers on a phase 2 study of an all-oral regimen—decitabine and cedazuridine plus venetoclax—for patients with newly diagnosed AML who are unfit for intensive induction. Dr. Fathi discusses the potential for these more convenient therapies to shift treatment into the outpatient se...
In this episode of The Hem Onc Pulse , Dr. Rahul Banerjee is joined by Dr. Michelle Longmire, CEO and co-founder of Medable, for a compelling discussion on drug accessibility in cancer care. Together, they explore how decentralized clinical trials and digital tools can help bridge the gap between cutting-edge therapies and the patients who need them most. Dr. Longmire shares how Medable is expanding access to clinical research, particularly in rural and underserved communities, by reimagining ho...
In this HemOnc Pulse Live ! edition of podcast, Dr. Mehdi Hamadani leads a comprehensive panel discussion on controversies and unanswered questions in the treatment of aggressive non-Hodgkin lymphoma. Dr. Hamadani is joined by Drs. Timothy Fenske, Madiha Iqbal, Urshila Durani, and Mohamed Kharfan-Dabaja.
In this episode of HemOnc Pulse , host Rahul Banerjee, MD, FACP of Fred Hutch Cancer Center is joined by myeloid malignancy expert Uma Borate, MBBS of The Ohio State University, for a high-impact discussion on one of hematology’s hottest frontiers: early detection. As aggressive diseases like AML and MDS continue to outpace traditional diagnostics, this conversation dives into why spotting these cancers sooner isn’t just helpful—it’s lifesaving.
In this special episode of our podcast, recorded live at HemOnc Pulse Live in Austin, Texas on May 2–3, 2025, leading experts tackle some of the most pressing controversies in the management of myelodysplastic syndromes. Moderated by Naval Daver, MD, this dynamic panel discussion brings together top thought leaders in hematologic malignancies to debate evolving treatment standards, diagnostic challenges, and the integration of emerging therapies in clinical practice.
In this episode of The HemOnc Pulse, Rahul Banerjee, MD of Fred Hutchinson Cancer Center is joined by Gurbakhash Kaur, MD of Mount Sinai for an in-depth discussion of the RedirecTT-1 trial, recently published in the New England Journal of Medicine . The conversation explores the evolving role of bispecific antibodies in multiple myeloma, with a focus on the combination of talquetamab (Tal) and teclistamab (TEC). Drs. Banerjee and Kaur unpack the trial’s rationale, design, and real-world implicat...
On this episode of "The HemOnc Pulse," Saad Usmani, MD, of the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss notable presentations on multiple myeloma from the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
On this episode of "The HemOnc Pulse," Chadi Nabhan, MD, MBA, FACP, is joined by Sangeetha Venugopal, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami, to highlight data on myelodysplastic syndromes (MDS) presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
On this episode of "The HemOnc Pulse," Naval Daver, MD, of the MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss news on acute myeloid leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
On this episode of "The HemOnc Pulse," Mazyar Shadman, MD, MPH, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to highlight some of the notable presentations on chronic lymphocytic leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
On this episode of "The HemOnc Pulse," Prithviraj Bose, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss some of the important data on myeloproliferative neoplasms that were presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
In part two of this episode, Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health, continue to explore the role of measurable residual disease (MRD) in the treatment of patients with chronic lymphocytic leukemia (CLL). “The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delv...
On “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, met with Afaf Osman, MD, an Assistant Professor at the University of Utah Huntsman Cancer Center, to discuss how high-risk myelodysplastic syndromes (MDS) are distinct from lower-risk classifications and how to approach treatment.
On “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, spoke with Rami Komrokji, MD, Vice Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida, about the state of myelodysplastic syndromes (MDS) care. Moffitt Cancer Center is home to a large MDS database, with clinical information on nearly 6,000 patients, a trove of real-world MDS data.
Part one of this episode explores questions in measurable residual disease (MRD) and chronic lymphocytic leukemia (CLL) with Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health. “The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in various ...
At the “HemOnc Pulse” Live meeting in Chicago, an expert panel explores unanswered questions in T-cell lymphoma management. The panelists were Mehdi Hamadani, MD, a Professor of Internal Medicine at the Medical College of Wisconsin, Andrew Evens, DO, MBA, MSc, Deputy Director for Clinical Services at Rutgers Cancer Center, and Barbara Pro, MD, a Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons.
Recorded at the first annual “HemOnc Pulse” Live meeting, this episode features a panel discussion on unanswered questions in myeloproliferative neoplasms (MPN) with Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center; Ruben Mesa, MD, of the Atrium Health cancer service line; Sanam Loghavi, MD, of the MD Anderson Cancer Center; and Olatoyosi Odenike, MD, of the University of Chicago Medicine.
“The HemOnc Pulse” was live for the first time in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in a range of hematologic malignancies. As part of the program, Michael Bishop MD, of the University of Chicago, and Aaron Goodman, MD, of the University of California, San Diego, were joined by Rafael Fonseca, MD, of the Mayo Clinic, to hold a panel on bispecific therapies and explor...
In this podcast episode covering the “HemOnc Pulse” Live meeting in Chicago, an expert panel explores unanswered questions in managing diffuse large B-cell lymphoma. The panelists included Grzegorz Nowakowski, MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic; Jane Winter, MD, a Professor of Medicine in the Division of Hematology and Oncology at the Northwestern University Feinberg School of Medicine; and Alan Skarbnik, MD, Director of the Lymphoma and Chr...
Recorded at the first “HemOnc Pulse” Live meeting in Chicago, this podcast episode features a panel discussion on unanswered questions in chronic myeloid leukemia (CML) with Elias Jabbour, MD, a Professor of Medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Mikkael Sekeres, MD, MS, a Professor of Medicine and Chief of the Division of Hematology at the University of Miami Sylvester Comprehensive Cancer Center; and Sangeetha Venugopal, MD, MS, an Assistan...
Recorded at the first “HemOnc Pulse” annual meeting, this podcast episode features a panel discussion on unanswered questions in acute lymphoblastic leukemia (ALL) with Elias Jabbour, MD, a Professor of Medicine at the University of Texas MD Anderson Cancer Center; Shira Dinner, MD, an Associate Professor of Medicine (Hematology and Oncology) at Northwestern Medicine; Sanam Loghavi, MD, an Associate Professor of Pathology at MD Anderson Cancer Center; and Wendy Stock, MD, Co-Leader of the Clinic...
Dr. Hilal, of the Mayo Clinic, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss measurable residual disease (MRD) and the debates surrounding its use for response assessment in patients with chronic lymphocytic leukemia (CLL).
Recorded at the first “HemOnc Pulse” Live meeting, this podcast episode features a panel discussion on unanswered questions in Hodgkin lymphoma with Andrew Evens, DO, MBA, MSc, Director of the Lymphoma Program and Associate Director of Rutgers Cancer Institute; Grzegorz Nowakowski, MD, a Professor of Oncology and Medicine in Division of Hematology at the Mayo Clinic; and Jane Winter, MD, a Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School...
Recorded at the first “HemOnc Pulse” Live meeting, this podcast episode features a panel discussion on unanswered questions in myelodysplastic syndromes (MDS) with Rami Komrokji, MD, Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center; Sanam Loghavi, MD, an Associate Professor of Pathology at the University of Texas MD Anderson Cancer Center; Jamile Shammo, MD, FACP, FASCP, a Professor at the Northwestern University Feinberg School of Medicine; Sangeetha Venugopal, MD, MS,...
This podcast episode features a panel discussion on challenges and opportunities for hematology oncology fellows with Megan Melody, MD, a third-year fellow at Northwestern University; Alexandra Rojek, MD, a second-year fellow at the University of Chicago Medicine Comprehensive Care Center; Seda Tolu, MD, a third-year fellow at the Columbia University Herbert Irving Comprehensive Cancer Center; Zaker Schwabkey, MD, a third-year fellow at Moffit Cancer Center; Himachandana Atluri, MD, a third-year...
“The HemOnc Pulse” goes on the road to Chicago May 3-4 with host Chadi Nabhan, MD, MBA, FACP, for the first live meeting. This podcast episode features a panel discussion on unanswered questions in chimeric antigen receptor (CAR) T-cell therapy with Caron Jacobson, MD, MMSc, Medical Director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute; Michael Bishop, MD, FACP, FASCO, Director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago; Jos...
"The HemOnc Pulse" goes on the road to Chicago with host Chadi Nabhan, MD, MBA, FACP. This podcast episode features a panel discussion on unanswered questions in acute myeloid leukemia (AML) with Naval Daver, MD, an Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Sanam Loghavi, MD, of the MD Anderson Cancer Center; Rami Komrokji, MD, the Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida; and Mikkae...
